Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system
Frontiers in Pharmacology · 14.04.2026 · 17
DOI: 10.3389/fphar.2026.1744180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.04.2026. Verfasst von Santosh Chokkakula und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Paroxetine, a selective serotonin reuptake inhibitor widely used in the management of major depressive disorders and other psychiatric disorders, remains insufficiently characterized regarding its adverse event spectrum. Thus, this study wanted to conduct a comprehensive evaluation of its post-marketing safety profile by analyzing reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods
Adverse event data related to paroxetine were extracted from the FAERS spanning the period from the first quarter of 2004 through the second quarter of 2025. Demographic distributions and reporter characteristics were analyzed to describe the exposed population. Signal detection was performed using four established disproportionality algorithms, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
Results
A total of 39,404 adverse event reports associated with paroxetine were included in the analysis. Female patients accounted for the majority of cases (57.41%), followed by males (32.84%). The most frequently reported preferred term (PT) was “drug withdrawal syndrome,” categorized under systemic diseases and administration site conditions, with 6,601 cases. This event demonstrated strong positive signals across all disproportionality metrics (ROR = 27.27, PRR = 26.31, χ 2 = 148,641, IC = 4.61, EBGM = 23.47). The highest signal strengths were observed within the SOC of congenital, familial, and genetic disorders. Notably, the PT “carcinogenic effect on offspring,” although reported only three times, exhibited markedly elevated values (ROR = 952.54, PRR = 952.52, χ 2 = 712.89, IC = 7.90, EBGM = 238.88), indicating an extremely disproportionate reporting frequency compared with baseline levels. Most adverse events (12.49%) appeared within the first 30 days of paroxetine therapy prescription.
Conclusion
The pharmacovigilance assessment of paroxetine systematically identified significant safety signals. These findings provide important post-marketing evidence to strengthen drug safety surveillance and facilitate more informed, patient-centered therapeutic decisions in clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea.
- Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Oncology Department 4, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Nursing Administration & Education Department, College of Nursing, King Saud University, Riyadh, Saudi Arabia.
- Department of Chemical and Biological Engineering, Gachon University, Seongnam-Si, Republic of Korea.
- Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Zitieren
APA
Chokkakula, S., Guo, Q., Zhang, X., Bin Jumah, J., Naveen, B., & Yang, B. (2026). Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744180
Vancouver
Chokkakula S, Guo Q, Zhang X, Bin Jumah J, Naveen B, Yang B. Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744180
BibTeX
@article{Chokkakula2026,
author = {Chokkakula, Santosh and Guo, Qian and Zhang, Xiaoyue and Bin Jumah, Jawaher and Naveen, Bommireddy and Yang, Bing},
title = {Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1744180}
}
EUVIMED